SEC 13F Intelligence

Managers / Q4 2022 · view latest →

Krensavage Asset Management, LLC

CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582

Reported Value
$324M
Q4 2022
Positions
12
Filings on Record
32
2019–present window
Filed
Feb 15, 2023
original filing

Summary

Krensavage Asset Management, LLC reported $324M in U.S.-listed holdings across 12 positions for Q4 2022.

Its largest position, UTHR, represents 16.5% of the portfolio.

Compared with Q3 2022, the fund opened 0 new positions and exited 2.

Portfolio Metrics

Turnover
+5.9%
vs prior filed quarter
Top-10 Concentration
+98.2%
share of reported value
Largest Position
+16.5%
United Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $370MQ1 ’19Q2 ’19: $308MQ3 ’19: $260MQ4 ’19: $293MQ1 ’20: $311MQ1 ’20Q2 ’20: $368MQ3 ’20: $314MQ4 ’20: $342MQ1 ’21: $289MQ1 ’21Q2 ’21: $295MQ3 ’21: $319MQ4 ’21: $288MQ1 ’22: $290MQ1 ’22Q2 ’22: $302MQ3 ’22: $314MQ4 ’22: $324MQ1 ’23: $329MQ1 ’23Q2 ’23: $316MQ3 ’23: $272MQ4 ’23: $282MQ1 ’24: $226MQ1 ’24Q2 ’24: $218MQ3 ’24: $178MQ4 ’24: $169MQ1 ’25: $181MQ1 ’25Q2 ’25: $189MQ3 ’25: $235MQ4 ’25: $283MQ1 ’26: $256MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 94.2%Other: 5.8%
  • Common Stock · 94.2% · $305M
  • Other · 5.8% · $19M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MCKMCKESSON CORPSOLD OUT−31.9K0−$11M$0
NEXTCURE INCSOLD OUT−31.3K0−$86,000$0
EXELEXELIXIS INCADDED+316.6K2.14M+$6M$34M
TARO PHARMACEUTICAL INDUSADDED+63.9K644.7K+$1M$19M
VNDAVANDA PHARMACEUTICALS INCADDED+33.0K345.3K−$534,000$3M
EGRXEAGLE PHARMACEUTICALS INCTRIMMED−6.3K114.8K+$157,000$3M
UTHRUNITED THERAPEUTICS CORPHELD−8.4K192.0K+$11M$53M
BIIBBIOGEN INCHELD−7.6K177.0K−$285,000$49M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1UTHRUNITED THERAPEUTICS CORPhistory →COM16.50%$53M192.0K
2BIIBBIOGEN INChistory →COM15.15%$49M177.0K
3REGNREGENERON PHARMACEUTICALShistory →COM13.40%$43M60.1K
4ALKSALKERMES PLChistory →COM11.32%$37M1.40M
5EXELEXELIXIS INChistory →COM10.60%$34M2.14M
6ENTAENANTA PHARMACEUTICALS INChistory →COM8.55%$28M594.8K
7EMBCEMBECTA CORPhistory →COM7.95%$26M1.02M
8CAHCARDINAL HEALTH INChistory →COM7.90%$26M332.7K
9TARO PHARMACEUTICAL INDUSCOM5.78%$19M644.7K
10EGRXEAGLE PHARMACEUTICALS INChistory →COM1.04%$3M114.8K
11KODKODIAK SCIENCES INChistory →COM1.03%$3M463.6K
12VNDAVANDA PHARMACEUTICALS INCCOM0.79%$3M345.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$256M20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$283M18Feb 18, 202613F-HRchanges · EDGAR ↗
Q3 2025$235M17Nov 17, 202513F-HRchanges · EDGAR ↗
Q2 2025$189M15Aug 15, 202513F-HRchanges · EDGAR ↗
Q1 2025$181M14May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$169M12Feb 18, 2025RESTATEMENTchanges · EDGAR ↗
Q3 2024$178M13Nov 15, 202413F-HRchanges · EDGAR ↗
Q2 2024$218M13Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$226M12May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$282M12Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$272M12Nov 15, 202313F-HRchanges · EDGAR ↗
Q2 2023$316M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$329M12May 16, 202313F-HRchanges · EDGAR ↗
Q4 2022$324M12Feb 15, 202313F-HRchanges · EDGAR ↗
Q3 2022$314M14Nov 15, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M14Aug 16, 202213F-HRchanges · EDGAR ↗
Q1 2022$290M13May 17, 202213F-HRchanges · EDGAR ↗
Q4 2021$288M10Feb 15, 202213F-HRchanges · EDGAR ↗
Q3 2021$319M13Nov 16, 202113F-HRchanges · EDGAR ↗
Q2 2021$295M13Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$289M12May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$342M12Feb 17, 202113F-HRchanges · EDGAR ↗
Q3 2020$314M11Dec 8, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$368M11Aug 20, 2020RESTATEMENTchanges · EDGAR ↗
Q1 2020$311M13May 18, 202013F-HRchanges · EDGAR ↗
Q4 2019$293M12Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$260M10Nov 15, 201913F-HRchanges · EDGAR ↗
Q2 2019$308M10Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$370M12May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.